Joshua Fox, MD
Dermatology · Fresh Meadows, NYNPI 1215937396
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $6,790 of the $8,538 with a category attached, or 79.5%. AbbVie accounts for 89.0% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2021 at $7,157 and has fallen 98.1% since, to $139 in 2025.
Across 82 payments — averaging $104.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$8K
- Novartis$150
- E.r. Squibb & Sons, L.L.C.$143
- Pfizer$111
- Regeneron Healthcare Solutions, Inc.$94
- Strata Skin Sciences, Inc.$83
- plus $362 from 10 others
What the payments were for
- Speaking & faculty fees$6,79080%
- Food & beverage$1,74820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 37 | $7,597 |
| Novartis | 6 | $150 |
| E.r. Squibb & Sons, L.L.C. | 6 | $143 |
| Pfizer | 5 | $111 |
| Regeneron Healthcare Solutions, Inc. | 1 | $94 |
| Strata Skin Sciences, Inc. | 11 | $83 |
| Sanofi | 1 | $74 |
| Merz North America, Inc. | 3 | $59 |
| Galderma Laboratories, L.p. | 3 | $55 |
| Organogenesis Inc. | 2 | $45 |
| Stryker | 2 | $37 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Sun Pharmaceutical Industries Inc. | 1 | $21 |
| Smith+Nephew | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
| Johnson & Johnson | 1 | $13 |
How this compares
$8,538 in reported general payments places this provider in the 70th percentile of 1,151 dermatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metronidazole | 29 | $2,546 |
| Fluocinonide | 53 | $2,294 |
| Clobetasol Propionate | 33 | $1,805 |
| Clindamycin Phosphate | 34 | $1,568 |
| Triamcinolone Acetonide | 97 | $1,265 |
| Ammonium Lactate | 74 | $1,246 |
| Econazole Nitrate | 27 | $826 |
| CiclopiroxCiclopirox Olamine | 23 | $729 |
| Hydrocortisone | 80 | $595 |
| Ketoconazole | 20 | $304 |
| Mupirocin | 30 | $242 |
| Minocycline Hcl | 15 | $160 |
| Hydroxyzine Hcl | 15 | $103 |
| Minoxidil | 20 | $81 |
| Levocetirizine Dihydrochloride | 11 | $58 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Fresh Meadows
- Alexandra GolantNew York$3.6M
- David CohenNew York$3M
- Michael CameronNew York$2.6M
- Saakshi KhattriNew York$2.4M
- Amy WechslerNew York$2.4M
- Jeffrey WeinbergKew Gardens$2.3M
- Joshua ZeichnerNew York$2.1M
- Russell CohenOceanside$2.1M
- Jeffrey LaducaAuburn$1.9M
- Emma GuttmanNew York$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.